Emmanuel Thomas

Summary

Affiliation: University of Miami
Country: USA

Publications

  1. doi The application and mechanism of action of ribavirin in therapy of hepatitis C
    Emmanuel Thomas
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, MD, USA
    Antivir Chem Chemother 23:1-12. 2013
  2. pmc Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C
    Yaron Rotman
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Gut 63:161-9. 2014
  3. pmc S-adenosyl methionine improves early viral responses and interferon-stimulated gene induction in hepatitis C nonresponders
    Jordan J Feld
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892 1800, USA
    Gastroenterology 140:830-9. 2011
  4. pmc HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons
    Emmanuel Thomas
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases National Institutes of Health, Bethesda, Maryland 20892, USA
    Gastroenterology 142:978-88. 2012
  5. pmc Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis
    Mazen Noureddin
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD
    Hepatology 58:1548-57. 2013
  6. ncbi Integrative functional genomics of hepatitis C virus infection identifies host dependencies in complete viral replication cycle
    Qisheng Li
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS Pathog 10:e1004163. 2014
  7. pmc Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models
    Emmanuel Thomas
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Hepatology 53:32-41. 2011

Collaborators

  • T Jake Liang
  • Jordan J Feld
  • Jay H Hoofnagle
  • David E Kleiner
  • Harel Dahari
  • Naveen Gara
  • Jeremie Guedj
  • Fang Zhang
  • Mazen Noureddin
  • Yaron Rotman
  • Qisheng Li
  • Marc G Ghany
  • Rachel Titerence
  • Catherine Sodroski
  • Theo Heller
  • Keng Hsin Lan
  • Su Hyung Park
  • Hwalih Han
  • Souvik Sarkar
  • Adil Abdalla
  • Leah Hogdal
  • Zongyi Hu
  • Yoon J Park
  • Yong Yuan Zhang
  • Edward Doo
  • Barbara Rehermann
  • Ching Sheng Hsu
  • Stephan Chiu
  • Michael Witthaus
  • Helen Cha
  • Golo Ahlenstiel
  • Birgit Edlich
  • Alan S Perelson
  • Christopher Koh
  • Harvey J Alter
  • Shauna Clark
  • Xiongce Zhao
  • Cathy Conry-Cantilena
  • Elizabeth C Wright
  • Richard Chen

Detail Information

Publications7

  1. doi The application and mechanism of action of ribavirin in therapy of hepatitis C
    Emmanuel Thomas
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, MD, USA
    Antivir Chem Chemother 23:1-12. 2013
    ..This review highlights the clinical application and mechanism of action of ribavirin and discusses the future role of ribavirin in treatment of HCV where there are intense research efforts to improve therapy...
  2. pmc Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C
    Yaron Rotman
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Gut 63:161-9. 2014
    ..Ribavirin improves treatment response to pegylated-interferon (PEG-IFN) in chronic hepatitis C but the mechanism remains controversial. We studied correlates of response and mechanism of action of ribavirin in treatment of hepatitis C...
  3. pmc S-adenosyl methionine improves early viral responses and interferon-stimulated gene induction in hepatitis C nonresponders
    Jordan J Feld
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892 1800, USA
    Gastroenterology 140:830-9. 2011
    ..We assessed the effect of SAMe on the kinetics of the early antiviral response and interferon signaling in nonresponders to previous antiviral therapy and investigated the mechanisms involved...
  4. pmc HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons
    Emmanuel Thomas
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases National Institutes of Health, Bethesda, Maryland 20892, USA
    Gastroenterology 142:978-88. 2012
    ..Little is known about the function of type III IFNs in intrinsic antiviral innate immunity...
  5. pmc Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis
    Mazen Noureddin
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD
    Hepatology 58:1548-57. 2013
    ....
  6. ncbi Integrative functional genomics of hepatitis C virus infection identifies host dependencies in complete viral replication cycle
    Qisheng Li
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS Pathog 10:e1004163. 2014
    ..This comprehensive study of HCV host dependencies yields novel insights into viral infection, pathogenesis and potential therapeutic targets. ..
  7. pmc Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models
    Emmanuel Thomas
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Hepatology 53:32-41. 2011
    ..RNA interference studies excluded the activation of the Toll-like receptor and nuclear factor κB pathways in the action of ribavirin...